Goal is to discover disease-modifying compounds based on the mechanism of the disease’s pathogenesis.
TorreyPines Therapeutics and Eisai extended their exclusive collaboration that began in February 2005. This agrement focuses on the discovery of novel, small molecules to treat Alzheimer’s disease.
The companies are studying the mechanism of the Alzheimer’s pathogenesis in the hope of finding disease modifying compounds.
Under the original agreement, Eisai has exclusive rights of first negotiation and refusal for validated compounds that are discovered through the research. TorreyPines and Eisai may enter into development agreements involving the validated compounds.
In a separate series of agreements, dating back to 2001, Eisai and TorreyPines are collaborating in a genetics program to discover Alzheimer’s disease targets using whole-genome, family-based association screening.